| 2025 | Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer
| JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE |
| 2024 | Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2024 | Reply to A. Okeya et al | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial | LANCET ONCOLOGY |
| 2024 | Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
| BREAST CANCER |
| 2024 | A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
| NPJ BREAST CANCER |
| 2024 | Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
| CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2024 | Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer
| ISCIENCE |
| 2024 | Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2-metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL. | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy
| CELL REPORTS MEDICINE |
| 2024 | Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
| BREAST CANCER RESEARCH AND TREATMENT |
| 2024 | Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2024 | Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
| ANNALS OF ONCOLOGY |
| 2024 | TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer | FUTURE ONCOLOGY |
| 2024 | Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
| CLINICAL CANCER RESEARCH |
| 2024 | A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2024 | Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial | EUROPEAN JOURNAL OF CANCER |
| 2023 | Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
| EUROPEAN JOURNAL OF CANCER |
| 2023 | Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
| JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH |
| 2023 | A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
| CANCER RESEARCH AND TREATMENT |
| 2023 | Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2023 | Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
| DIAGNOSTICS |
| 2023 | Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2023 | Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
| ESMO OPEN |
| 2023 | Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2023 | A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
| CANCER RESEARCH AND TREATMENT |
| 2023 | Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA
| NATURE COMMUNICATIONS |
| 2023 | Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2023 | Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
| CANCER SCIENCE |
| 2023 | Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
| CANCER RESEARCH AND TREATMENT |
| 2023 | Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK |
| 2023 | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
| BREAST CANCER RESEARCH |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2023 | Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
| CANCER MEDICINE |
| 2022 | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) | BREAST |
| 2022 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
| JAMA ONCOLOGY |
| 2022 | Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| 2022 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer
| CANCERS |
| 2022 | Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant | CLINICAL CANCER RESEARCH |
| 2022 | Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
| ANNALS OF ONCOLOGY |
| 2022 | Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
| CLINICAL CANCER RESEARCH |
| 2021 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
| ANNALS OF ONCOLOGY |
| 2021 | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer | CLINICAL CANCER RESEARCH |
http://orcid.org/0000-0002-2303-2764
(15045889800)
